1. Home
  2. Vol 55, No 1 (2023)
  3. Wahyudi

Efficacy and Safety of Clopidogrel in the Prevention of Primary Failure of Arteriovenous Fistula in Patients with End-Stage Renal Disease: A Systematic Review

Wahyudi Wahyudi, Dono Antono, Pringgodigdo Nugroho, Ikhwan Rinaldi, Ika Prasetya Wijaya, Hamzah Shatri, Em Yunir, Lusiani Rusdi

Abstract


Background: Arteriovenous fistula (FAV) is the most widely used vascular access for end-stage renal disease (ESRD) patients undergoing routine hemodialysis in Indonesia. However, FAV can become dysfunctional before it is used for the initiation of hemodialysis, a condition known as primary failure. Clopidogrel is an anti-platelet aggregation that has been reported to reduce the incidence of primary failure in FAV compared to other anti-platelet aggregation agents. Through this systematic review, we aimed to assess the role of clopidogrel to the incidence of primary FAV failure and the risk of bleeding in ESRD patients. Methods: A literature search was carried out to obtain randomized Control Trial studies conducted since 1987 from Medline / Pubmed, EbscoHost, Embase, Proquest, Scopus, and Cochrane Central without language restrictions. Risk of bias assessment was performed with the Cochrane Risk of Bias 2 application. Results: All of the three studies involved indicated the benefit of clopidogrel for the prevention of AVF primary failure. However, all of the studies have substantial differences. Abacilar’s study included only participants with diabetes mellitus. This study also administered a combination of clopidogrel 75 mg and prostacyclin 200 mg/day, while Dember’s study gave an initial dose of clopidogrel 300 mg followed by daily dose 75 mg and Ghorbani’s study only gave clopidogrel 75 mg/day. Ghorbani and Abacilar started the intervention 7-10 days before AVF creation, while Dember started 1 day after VAF creation. Dember gave treatment for 6 weeks with an assessment of primary failure at the end of week 6, Ghorbani’s treatment lasted for 6 weeks with an assessment at week 8, while Abacilar gave treatment for one year with an assessment at weeks 4 after AVF creation. In addition, the prevalence of bleeding did not differ between the treatment and control groups. Conclusion: Clopidogrel can reduce the incidence of primary FAV failure without significant increase of bleeding events.


Keywords


arteriovenous fistula; primary failure; clopidogrel; end-stage renal disease; systematic review

References


PERNEFRI. 11th Report of Indonesian Renal Registry 2018. 2018:1–46.

Lok CE, Huber TS, Lee T, et al. KDOQI clinical practice guideline for vascular access: 2019 Update. Am J Kidney Dis. 2020;75(4):S1–164.

Quencer KB, Oklu R. Hemodialysis access thrombosis. Cardiovasc Diagn Ther. 2017;7(3):S299–308.

Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial. J Am Med Assoc. 2008;299(18):2164–71.

Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian J Nephrol. 2009;19(2):57–61.

Abacilar AF, Atalay H, Dogan OF. Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: A randomized controlled study. Indian J Nephrol. 2015;25(3):136–42.

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

Tawfik A, Elshimy W. Clopidogrel versus acetyl salicylic acid in arteriovenous fistula salvage. Egyptian J Surg. 2015;34(4):222.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.3. Cochrane; 2022.

Misskey J, Faulds J, Sidhu R, Baxter K, Gagnon J, Hsiang Y. An age-based comparison of fistula location, patency, and maturation for elderly renal failure patients. J Vasc Surg. 2018;67(5):1491–500.

Lok CE, Oliver MJ, Su J, Bhola C, Hannigan N, Jassal SV. Arteriovenous fistula outcomes in the era of the elderly dialysis population. Kidney Intern. 2005;67.

Miller CD, Robbin ML, Allon M. Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients. Kidney Int. 2003;63(1):346–52.

Marcus RJ, Marcus DA, Sureshkumar KK, Hussain SM, McGill RL. Gender differences in vascular access in hemodialysis patients in the United States: Developing strategies for improving access outcome. Gend Med. 2007;4(3):193–204.

Lin SL, Huang CH, Chen HS, Hsu WA, Yen CJ, Yen TS. Effects of age and diabetes on blood flow rate and primary outcome of newly created hemodialysis arteriovenous fistulas. Am J Nephrol. 1998;18(2):96–100.

Afsar B, Elsurer R. The primary arteriovenous fistula failure-A comparison between diabetic and non-diabetic patients: Glycemic control matters. Int Urol Nephrol. 2012;44(2):575–81.

Gurbel PA, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Exp Opin Drug Metab Toxicol. 2009;5:989–1004.

Stitham J, Midgett C, Martin KA, Hwa J. Prostacyclin: An inflammatory paradox. Front Pharmacol. 2011.

Warnholtz A, Ostad MA, Velich N, et al. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double-blind, randomized study. Atherosclerosis. 2008;196(2):689–95.

Quinn MJ, Bhatt DL, Zidar F, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004;93(6):679–84.

Antonino MJ, Mahla E, Bliden KP, Tantry US, Gurbel PA. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol. 2009;103(11):1546–50.

Froldi G, Bertin R, Dorigo P, Montopoli M, Caparrotta L. Endothelium-independent vasorelaxation by ticlopidine and clopidogrel in rat caudal artery. J Pharm Pharmacol. 2011;63(8):1056–62.

Lin T, Lai W, Hsin H, Li A, Wang C, Kuo C. Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. 2013;8(8):1–9.


Full Text: PDF

Refbacks

  • There are currently no refbacks.